{"id":"5-fluorouracil-5-fu","safety":{"commonSideEffects":[{"effect":"Diarrhoea","drugRate":"49.2%","placeboRate":"","totalAtRisk":2319,"totalAffected":1140,"trialsReporting":7},{"effect":"Nausea","drugRate":"45.6%","placeboRate":"","totalAtRisk":2319,"totalAffected":1058,"trialsReporting":7},{"effect":"DIARRHOEA","drugRate":"71.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":834,"trialsReporting":2},{"effect":"Peripheral sensory neuropathy","drugRate":"35.0%","placeboRate":"","totalAtRisk":2279,"totalAffected":798,"trialsReporting":6},{"effect":"Fatigue","drugRate":"21.6%","placeboRate":"","totalAtRisk":3645,"totalAffected":786,"trialsReporting":8},{"effect":"Neutrophil count decreased","drugRate":"33.8%","placeboRate":"","totalAtRisk":2279,"totalAffected":771,"trialsReporting":6},{"effect":"NAUSEA","drugRate":"60.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":709,"trialsReporting":2},{"effect":"Neutropenia","drugRate":"27.4%","placeboRate":"","totalAtRisk":2319,"totalAffected":636,"trialsReporting":7},{"effect":"Vomiting","drugRate":"27.4%","placeboRate":"","totalAtRisk":2319,"totalAffected":636,"trialsReporting":7},{"effect":"Stomatitis","drugRate":"25.3%","placeboRate":"","totalAtRisk":2319,"totalAffected":587,"trialsReporting":7},{"effect":"Constipation","drugRate":"22.3%","placeboRate":"","totalAtRisk":2319,"totalAffected":516,"trialsReporting":7},{"effect":"Anaemia","drugRate":"32.8%","placeboRate":"","totalAtRisk":1540,"totalAffected":505,"trialsReporting":6},{"effect":"FATIGUE","drugRate":"42.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":502,"trialsReporting":2},{"effect":"Hypertension","drugRate":"14.6%","placeboRate":"","totalAtRisk":3058,"totalAffected":446,"trialsReporting":7},{"effect":"Rash","drugRate":"28.2%","placeboRate":"","totalAtRisk":1540,"totalAffected":434,"trialsReporting":6},{"effect":"Asthenia","drugRate":"18.6%","placeboRate":"","totalAtRisk":2319,"totalAffected":431,"trialsReporting":7},{"effect":"STOMATITIS ALL","drugRate":"63.8%","placeboRate":"","totalAtRisk":657,"totalAffected":419,"trialsReporting":1},{"effect":"NEUTROPENIA","drugRate":"35.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":411,"trialsReporting":2},{"effect":"RASH","drugRate":"33.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":396,"trialsReporting":2},{"effect":"Pyrexia","drugRate":"16.4%","placeboRate":"","totalAtRisk":2319,"totalAffected":380,"trialsReporting":7},{"effect":"Decreased appetite","drugRate":"39.9%","placeboRate":"","totalAtRisk":953,"totalAffected":380,"trialsReporting":5},{"effect":"VOMITING","drugRate":"30.4%","placeboRate":"","totalAtRisk":1175,"totalAffected":357,"trialsReporting":2},{"effect":"Alopecia","drugRate":"18.6%","placeboRate":"","totalAtRisk":1821,"totalAffected":338,"trialsReporting":6},{"effect":"ANOREXIA","drugRate":"26.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":312,"trialsReporting":2},{"effect":"CONSTIPATION","drugRate":"25.4%","placeboRate":"","totalAtRisk":1175,"totalAffected":299,"trialsReporting":2},{"effect":"Weight decreased","drugRate":"18.2%","placeboRate":"","totalAtRisk":1540,"totalAffected":281,"trialsReporting":6},{"effect":"ALOPECIA","drugRate":"23.0%","placeboRate":"","totalAtRisk":1175,"totalAffected":270,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"17.2%","placeboRate":"","totalAtRisk":1540,"totalAffected":265,"trialsReporting":6},{"effect":"White blood cell count decreased","drugRate":"28.9%","placeboRate":"","totalAtRisk":916,"totalAffected":265,"trialsReporting":4},{"effect":"ABDOMINAL PAIN","drugRate":"21.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":250,"trialsReporting":2},{"effect":"Platelet count decreased","drugRate":"26.1%","placeboRate":"","totalAtRisk":916,"totalAffected":239,"trialsReporting":4},{"effect":"Epistaxis","drugRate":"12.9%","placeboRate":"","totalAtRisk":1821,"totalAffected":234,"trialsReporting":6},{"effect":"Hypokalaemia","drugRate":"14.9%","placeboRate":"","totalAtRisk":1540,"totalAffected":229,"trialsReporting":6},{"effect":"Aspartate aminotransferase increased","drugRate":"23.2%","placeboRate":"","totalAtRisk":953,"totalAffected":221,"trialsReporting":5},{"effect":"Pruritus","drugRate":"14.1%","placeboRate":"","totalAtRisk":1540,"totalAffected":217,"trialsReporting":6},{"effect":"ANAEMIA","drugRate":"17.8%","placeboRate":"","totalAtRisk":1175,"totalAffected":209,"trialsReporting":2},{"effect":"Decreased Appetite","drugRate":"26.4%","placeboRate":"","totalAtRisk":779,"totalAffected":206,"trialsReporting":1},{"effect":"Insomnia","drugRate":"8.6%","placeboRate":"","totalAtRisk":2319,"totalAffected":200,"trialsReporting":7},{"effect":"HYPOKALAEMIA","drugRate":"16.3%","placeboRate":"","totalAtRisk":1175,"totalAffected":192,"trialsReporting":2},{"effect":"Headache","drugRate":"8.2%","placeboRate":"","totalAtRisk":2319,"totalAffected":191,"trialsReporting":7},{"effect":"Cough","drugRate":"8.2%","placeboRate":"","totalAtRisk":2319,"totalAffected":191,"trialsReporting":7},{"effect":"Dyspnoea","drugRate":"8.2%","placeboRate":"","totalAtRisk":2319,"totalAffected":189,"trialsReporting":7},{"effect":"DRY SKIN","drugRate":"15.7%","placeboRate":"","totalAtRisk":1175,"totalAffected":184,"trialsReporting":2},{"effect":"ASTHENIA","drugRate":"15.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":183,"trialsReporting":2},{"effect":"Alanine aminotransferase increased","drugRate":"19.2%","placeboRate":"","totalAtRisk":953,"totalAffected":183,"trialsReporting":5},{"effect":"DYSGEUSIA","drugRate":"15.4%","placeboRate":"","totalAtRisk":1175,"totalAffected":181,"trialsReporting":2},{"effect":"Palmar-plantar erythrodysaesthesia syndrome","drugRate":"11.9%","placeboRate":"","totalAtRisk":1502,"totalAffected":179,"trialsReporting":4},{"effect":"DERMATITIS ACNEIFORM","drugRate":"34.6%","placeboRate":"","totalAtRisk":518,"totalAffected":179,"trialsReporting":1},{"effect":"Dermatitis acneiform","drugRate":"24.8%","placeboRate":"","totalAtRisk":718,"totalAffected":178,"trialsReporting":4},{"effect":"PYREXIA","drugRate":"14.6%","placeboRate":"","totalAtRisk":1175,"totalAffected":171,"trialsReporting":2}]},"_chembl":null,"_fixedAt":"2026-03-30T11:31:42.969875","allNames":"5-fluorouracil (5-fu)","_dailymed":null,"mechanism":{"target":"TYMS","drugClass":"Antimetabolite","explanation":"5-Fluorouracil works by blocking an enzyme called thymidylate synthase, which is crucial for making DNA. This disruption prevents cancer cells from reproducing and spreading.","oneSentence":"5-Fluorouracil (5-FU) inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells."},"_scrapedAt":"2026-03-28T04:11:21.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:54:10.636651+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_fixedFields":["pubmed(13561)"],"trialDetails":[{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT06820463","phase":"PHASE2","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-24","conditions":"Metastatic Colorectal Cancer","enrollment":390},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07011576","phase":"PHASE2","title":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2025-09-29","conditions":"Colon Cancer, Rectal Cancer, Colorectal Cancer","enrollment":60},{"nctId":"NCT05464030","phase":"PHASE1","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","status":"RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-04","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT04808323","phase":"PHASE1","title":"MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-06-17","conditions":"Rectal Adenocarcinoma","enrollment":22},{"nctId":"NCT06469944","phase":"PHASE1, PHASE2","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-09-20","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":160},{"nctId":"NCT06131840","phase":"PHASE1","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2023-11-20","conditions":"Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms","enrollment":914},{"nctId":"NCT06731803","phase":"PHASE1, PHASE2","title":"Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-03-25","conditions":"Esophagogastric Adenocarcinoma","enrollment":36},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT07069712","phase":"PHASE2","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-17","conditions":"Gastroesophageal Adenocarcinoma","enrollment":100},{"nctId":"NCT06780111","phase":"PHASE1, PHASE2","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":298},{"nctId":"NCT05174169","phase":"PHASE2, PHASE3","title":"Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2022-03-10","conditions":"Stage III Colon Cancer","enrollment":1912},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT04068610","phase":"PHASE1, PHASE2","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2019-09-13","conditions":"Metastatic Microsatellite-stable Colorectal Cancer","enrollment":61},{"nctId":"NCT05382559","phase":"PHASE1","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Inc","startDate":"2022-06-08","conditions":"Solid Tumor","enrollment":681},{"nctId":"NCT06657144","phase":"PHASE1","title":"A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Coherus Oncology, Inc.","startDate":"2025-04-01","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor","enrollment":154},{"nctId":"NCT07437287","phase":"PHASE2, PHASE3","title":"Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-07","conditions":"Biliary Tract Cancer (BTC)","enrollment":160},{"nctId":"NCT04379596","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2020-06-03","conditions":"Gastric Cancer","enrollment":450},{"nctId":"NCT05647122","phase":"PHASE1","title":"First in Human Study of AZD9592 in Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-12-21","conditions":"Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms","enrollment":403},{"nctId":"NCT07419464","phase":"PHASE2","title":"5-Fluorouracil Response and Optimization STudy (The FROST Trial)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":46},{"nctId":"NCT05413811","phase":"NA","title":"Acceptability and Feasibility of Combination Treatment for Cervical Precancer Among South African Women Living With HIV","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-03-22","conditions":"Cervical Cancer, CIN2, CIN3","enrollment":180},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT07401277","phase":"PHASE1","title":"Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum","status":"NOT_YET_RECRUITING","sponsor":"West Virginia University","startDate":"2026-03","conditions":"Actinic Keratoses","enrollment":32},{"nctId":"NCT07400315","phase":"PHASE2","title":"First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":64},{"nctId":"NCT06662006","phase":"PHASE2","title":"Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-03-01","conditions":"Advanced Metastatic Pancreatic Cancer","enrollment":56},{"nctId":"NCT03784326","phase":"PHASE2","title":"Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-02-19","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":43},{"nctId":"NCT07030283","phase":"PHASE1","title":"Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-12-31","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":10},{"nctId":"NCT07381309","phase":"PHASE2","title":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Jun Huang","startDate":"2026-02-01","conditions":"CRC, Liver Metastasis Colon Cancer","enrollment":114},{"nctId":"NCT07372300","phase":"PHASE3","title":"Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shih-Kai Hung","startDate":"2025-09-23","conditions":"Locally Advanced Rectal Carcinoma","enrollment":126},{"nctId":"NCT04421820","phase":"PHASE1, PHASE2","title":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","status":"RECRUITING","sponsor":"Bold Therapeutics, Inc.","startDate":"2020-08-28","conditions":"Colorectal Cancer, Pancreatic Cancer, Gastric Cancers","enrollment":220},{"nctId":"NCT04643366","phase":"PHASE2","title":"Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2021-01-28","conditions":"Rectal Cancer","enrollment":54},{"nctId":"NCT05009069","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-18","conditions":"Rectal Neoplasms, Rectal Cancer","enrollment":58},{"nctId":"NCT07359456","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-03","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT06428409","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-20","conditions":"Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer","enrollment":220},{"nctId":"NCT06792695","phase":"PHASE2","title":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-12","conditions":"Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT06362226","phase":"PHASE1","title":"Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-02-28","conditions":"Periorbital Burns","enrollment":10},{"nctId":"NCT06106308","phase":"PHASE2","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff Oncology","startDate":"2024-02-27","conditions":"Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation","enrollment":113},{"nctId":"NCT07325214","phase":"NA","title":"Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"IMGT Co., Ltd.","startDate":"2026-04","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer","enrollment":136},{"nctId":"NCT04689347","phase":"PHASE1, PHASE2","title":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2021-01-01","conditions":"Metastatic Colorectal Cancer","enrollment":27},{"nctId":"NCT07317583","phase":"NA","title":"Improving 5-Fluorouracil (5-FU) Continuous Infusion Comfort With a New Corset Design in People Affected by Cancer","status":"COMPLETED","sponsor":"Istanbul University - Cerrahpasa","startDate":"2024-04-10","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT07283848","phase":"PHASE2","title":"Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2026-02-01","conditions":"Adenocarcinoma Stomach, Adenocarcinoma Gastroesophageal Junction","enrollment":""},{"nctId":"NCT04752696","phase":"PHASE2","title":"Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2021-05-25","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":41},{"nctId":"NCT06509906","phase":"PHASE1","title":"M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-10-08","conditions":"Advanced Solid Tumor","enrollment":3},{"nctId":"NCT07267806","phase":"PHASE3","title":"Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC","status":"RECRUITING","sponsor":"Linhui Peng","startDate":"2025-10-31","conditions":"Hepato Cellular Carcinoma (HCC), Chemotherapy Effect","enrollment":326},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT06733038","phase":"PHASE3","title":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-11-15","conditions":"Colorectal Cancer","enrollment":238},{"nctId":"NCT06941857","phase":"PHASE2","title":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-09-04","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06172205","phase":"PHASE3","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-07-01","conditions":"BCLC Stage C Hepatocellular Carcinoma, Chemotherapy Effect","enrollment":262},{"nctId":"NCT07256782","phase":"PHASE1, PHASE2","title":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-10-24","conditions":"Advanced Solid Tumor","enrollment":444},{"nctId":"NCT06846346","phase":"PHASE2","title":"Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-20","conditions":"Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma","enrollment":88},{"nctId":"NCT07201766","phase":"NA","title":"The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.","status":"NOT_YET_RECRUITING","sponsor":"King Edward Medical University","startDate":"2025-12-02","conditions":"Keloids Scars","enrollment":104},{"nctId":"NCT06632717","phase":"PHASE2","title":"Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-09-01","conditions":"Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT04854499","phase":"PHASE2","title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-09-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":193},{"nctId":"NCT06328738","phase":"PHASE1","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Enliven Therapeutics","startDate":"2024-05-30","conditions":"HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors","enrollment":275},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT05077800","phase":"PHASE2","title":"FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-03-21","conditions":"Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic","enrollment":70},{"nctId":"NCT06529718","phase":"PHASE2","title":"Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-10-09","conditions":"Biliary Tract Cancer","enrollment":72},{"nctId":"NCT03161522","phase":"PHASE2","title":"Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-19","conditions":"Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7","enrollment":100},{"nctId":"NCT04185883","phase":"PHASE1","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2019-12-17","conditions":"Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation","enrollment":610},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT06851507","phase":"PHASE3","title":"A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-06","conditions":"Multiple Actinic Keratoses","enrollment":30},{"nctId":"NCT03184870","phase":"PHASE1, PHASE2","title":"A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-08-08","conditions":"Colorectal Cancer, Pancreatic Cancer","enrollment":332},{"nctId":"NCT07204574","phase":"PHASE1, PHASE2","title":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-05-14","conditions":"CRC","enrollment":40},{"nctId":"NCT05609370","phase":"PHASE1, PHASE2","title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-29","conditions":"Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer","enrollment":113},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT03563248","phase":"PHASE2","title":"Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-08-10","conditions":"Pancreatic Cancer","enrollment":168},{"nctId":"NCT04595266","phase":"PHASE2","title":"Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2021-06-29","conditions":"Colorectal Cancer Metastatic, Liver Metastasis Colon Cancer","enrollment":48},{"nctId":"NCT05052099","phase":"PHASE1, PHASE2","title":"Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2021-10-22","conditions":"Biliary Tract Cancer","enrollment":20},{"nctId":"NCT07173387","phase":"PHASE2","title":"Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-10-01","conditions":"Pancreatic Cancer","enrollment":42},{"nctId":"NCT03929666","phase":"PHASE2","title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2019-08-29","conditions":"HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","enrollment":74},{"nctId":"NCT00082706","phase":"PHASE2","title":"Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-04-23","conditions":"Bladder Cancer, Urethral Cancer, Urachal Cancer","enrollment":46},{"nctId":"NCT06936527","phase":"PHASE1, PHASE2","title":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","status":"ENROLLING_BY_INVITATION","sponsor":"NovaOnco Therapeutics Co., Ltd.","startDate":"2025-05-23","conditions":"Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation","enrollment":102},{"nctId":"NCT02008656","phase":"PHASE2","title":"Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-11","conditions":"Rectal Cancer","enrollment":358},{"nctId":"NCT07018570","phase":"PHASE2","title":"An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2025-07-24","conditions":"Gastroesophageal Junction (GEJ) Adenocarcinoma","enrollment":26},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT06958419","phase":"PHASE2, PHASE3","title":"Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-05-01","conditions":"Immune Checkpoint Therapy, Radiotherapy, Metastatic Colorectal Cancer (CRC)","enrollment":286},{"nctId":"NCT03783442","phase":"PHASE3","title":"A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-11","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":649},{"nctId":"NCT03636893","phase":"PHASE2","title":"Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2018-08-24","conditions":"Gastric Cancer, Chemotherapy Effect","enrollment":74},{"nctId":"NCT02059499","phase":"PHASE3","title":"Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2015-12-28","conditions":"Anal Intraepithelial Neoplasia, High-grade Squamous Intraepithelial Lesion, HIV Infection","enrollment":91},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT07047560","phase":"PHASE2","title":"Liposomal Irinotecan (II) Fractionated Dosing Combined With 5-FU/LV (FOLFIRInali-3) and Bevacizumab in Second-line Treatment of Advanced Colorectal Cancer: A Single-arm, Phase II Clinical Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-09-01","conditions":"Colorectal Cancer (CRC)","enrollment":46},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT04420884","phase":"PHASE1, PHASE2","title":"A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2020-07-22","conditions":"Solid Neoplasms","enrollment":248},{"nctId":"NCT01804790","phase":"PHASE3","title":"Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2012-01","conditions":"Cancer of the Rectum","enrollment":461},{"nctId":"NCT04554836","phase":"PHASE2","title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","status":"COMPLETED","sponsor":"TheraOp","startDate":"2020-12-29","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":6},{"nctId":"NCT06005324","phase":"PHASE1","title":"Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2023-12-18","conditions":"HPV-Negative Squamous Cell Carcinoma","enrollment":36},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT02720068","phase":"PHASE1","title":"Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-02","conditions":"Neoplasms","enrollment":481},{"nctId":"NCT02138617","phase":"PHASE2","title":"Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05-06","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT06794086","phase":"PHASE3","title":"SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases","status":"RECRUITING","sponsor":"Jun Huang","startDate":"2025-04-10","conditions":"Colorectal Cancer, Liver Metastases","enrollment":24},{"nctId":"NCT02795988","phase":"PHASE1, PHASE2","title":"A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Imugene Limited","startDate":"2017-08-30","conditions":"Gastrointestinal Neoplasms, Adenocarcinoma","enrollment":64},{"nctId":"NCT05004350","phase":"PHASE2","title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2021-09-14","conditions":"BRAF V600E, Metastatic Colorectal Cancer","enrollment":107},{"nctId":"NCT04256707","phase":"PHASE1, PHASE2","title":"Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-01-14","conditions":"Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors","enrollment":126},{"nctId":"NCT02688712","phase":"PHASE2","title":"ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2016-03-24","conditions":"Rectal Adenocarcinoma","enrollment":50},{"nctId":"NCT06856447","phase":"PHASE1","title":"The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","status":"RECRUITING","sponsor":"toqa saad mohammed mohammed","startDate":"2024-06-01","conditions":"Colorectal Cancer","enrollment":22},{"nctId":"NCT03829410","phase":"PHASE1, PHASE2","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2019-06-24","conditions":"Metastatic Colorectal Cancer, KRAS Gene Mutation","enrollment":68},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13561,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"5-Fluorouracil (5-FU)","genericName":"5-fluorouracil-5-fu","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":5,"trialStats":{"total":24,"withResults":12},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:54:10.636651+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}